Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over
January 13, 2011
Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over
Some players in the field cautioned that the industry may be too focused on lipid delivery, potentially passing over other technologies that, while at an earlier stage of development, may ultimately be successful for certain indications.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In 2010, RNAi Moves into the Mainstream, microRNAs Continue to Garner Interest
January 6, 2011 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide
July 19, 2012 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Tekmira Says USPTO Declares Interference for Alnylam Patent as Firms Continue Litigation
October 20, 2011 / Gene Silencing News